Effect of BMS-650032 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri- Cyclen (R)) in Healthy Female Subjects.

Trial Profile

Effect of BMS-650032 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri- Cyclen (R)) in Healthy Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2010

At a glance

  • Drugs Asunaprevir; Ethinylestradiol/norgestimate
  • Indications Hepatitis C; Menopausal syndrome; Pregnancy
  • Focus Pharmacokinetics
  • Most Recent Events

    • 29 Jun 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
    • 29 Jun 2010 Actual end date added to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 29 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top